Meet with Ontada
at ASH Annual Meeting 2026
December 12 - 15 | New Orleans (Ernest N. Morial Convention Center)
VISIT US AT BOOTH 2059
ASH is rapidly approaching, and we look forward to connecting. To meet with the Ontada team at ASH and learn more about our real-world oncology data and research solutions, fill out the form to set up a meeting.
You can also find us at Booth #2059.
Be sure to ask about our newest solution, ON.Journey, our off-the-shelf research-grade RWD solution. ON.Journey integrates structured and unstructured data from The U.S. Oncology Network, the largest community oncology network in the U.S., to deliver a uniquely granular, longitudinal view of real-world cancer care.
Scroll down to learn about the research we will be presenting.
ASH 2026 presentations
Effectiveness of early first-line luspatercept use in patients with lower-risk myelodysplastic syndromes: a real-world analysis from Florida Cancer Specialists & Research Institute
Saturday, Dec 12, 5:30 – 7:30 p.m.
Presenters: Fonseca Gustavo, MD, Amanda K. Warner
Authors: Dr. Fonseca Gustavo, Amanda K. Warner, Christian Okitondo, Hannah Dracos
Publication #: 2669
Patient characteristics, treatment patterns, complete hematologic response, and disease progression among patients with polycythemia vera treated with ropeginterferon alfa-2b in US community oncology practice
TBA
Presenter: Harry Menon
Authors: Harry Menon, Victoria Vardell, Andrew J. Osterland, Malcolm Charles, Matthew Whitesell, Bryanne Tedesco, Bela Bapat, Shinya Imada, Shaoyu Chang, Albert Qin, Ira Zackon, Luke Fletcher, Mark G. Faber
Publication #: TBD
Real-World Epidemiology, Treatment Patterns, and Survival in Chronic Myelomonocytic Leukemia: A Study of Patients in the U.S. Community Oncology Setting
Monday, Dec 14, 6:00 – 8:00 p.m.
Presenter: Alisha Monnette Kimble
Authors: Alisha Monnette Kimble, Robert Reid, Junxin Shi, Debra Rembert, Margret Merino, Martha Donoghue, Arup K. Sinha, Fatima Rizvi
Publication #: 6363
ONLINE PUBLICATIONS
Real-World Epidemiology, Treatment Patterns, and Clinical Outcomes of Mantle Cell Lymphoma: A Study of Patients in the U.S. Community Oncology Setting
Authors: Alisha Monnette Kimble, Robert Reid, Junxin Shi, Debra Rembert, Margret Merino, Martha Donoghue, Arup K. Sinha, Fatima Rizvi
First-line polatuzumab vedotin plus R-CHP in previously untreated diffuse large B-cell lymphoma patients: real-world clinical outcomes in US community oncology practices
Authors: Ira Zackon, Carole Berini, Jinhong Guo, Anthony Masaquel, Yong Mun, Lourenia Cassoli, Carolina Reyes, John M. Burke
Real-world characteristics. treatment patterns, and outcomes of patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL), Not Otherwise Specified (NOS), treated in first-line (1L) by Cell-of-Origin (COO) in United States (US) community oncology practices
Authors: Barbara Furtado, Helen Latimer, Ira Zackon, Daniel Huang, Marc Purazo, Debbie Adkins, Debra Rembert, Jinhong Guo, Helen Engle, David Andorsky
Meet Our Team at ASH 2026
Reach out to our team for an ASH meetup or fill out our form. We look forward to seeing you in New Orleans!
